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ABSTRACT
Ventilator-associated pneumonia (VAP) remains 
a leading cause of morbidity and mortality 
in mechanically-ventilated patients in the 
Intensive Care Unit (ICU). Ventilator-associated 
tracheobronchitis (VAT) was previously 
believed to be an intermediate stage between 
colonization of the lower respiratory tract and 
VAP. More recent data, however, suggest that 
VAT may be a separate entity that increases 
morbidity and mortality, independently of the 
occurrence of VAP. Some, but not all, patients 
with VAT progress to develop VAP. Although 
inhaled antibiotics alone could be effective for 
the treatment of VAP, the current consensus 
of opinion favors their role as adjuncts to 
systemic antimicrobial therapy for VAP. Inhaled 
antibiotics are increasingly employed for 
salvage therapy in patients with VAP due to 
multi-drug resistant Gram-negative bacteria. In 
contrast to VAP, VAT could be effectively treated 
with inhaled antibiotic therapy alone or in 
combination with systemic antimicrobials.
Keywords: aerosols; antibiotic resistance; 
antibiotics; colistin; Gram-negative pneumonia; 
levofloxacin; mechanical ventilation; nebulizer; 
tracheobronchitis
INTRODUCTION
Placement of an endotracheal tube increases 
the risk of developing pneumonia among 
mechanically-ventilated patients by 6-20 fold 
compared to critically ill patients who are 
not intubated.1 Development of ventilator-
associated pneumonia (VAP) is undoubtedly 
associated with significant morbidity and 
mortality, particularly when it is associated 
with bacteremia due to multi-drug resistant 
(MDR) organisms.1-3 Inhaled antibiotics are 
useful adjuncts to systemic antibiotic therapy 
for reducing morbidity and mortality due to 
VAP, especially pneumonia caused by MDR 
pathogens.4,5
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Ventilator-associated tracheobronchitis (VAT) 
was previously considered to be an intermediate 
step between oropharyngeal colonization 
and VAP,6 and specific antibiotic therapy was 
generally not recommended for its treatment. 
Recent findings indicate that VAT may not 
precede VAP and may be an independent entity 
that is associated with significant morbidity 
and mortality per se.7,8 The optimal antibiotic 
regimen(s) and route(s) of administration for 
treatment of VAT have not been established 
as yet. The purpose of the current review 
paper is to discuss the terminology of VAT and 
VAP, explain the rationale for using inhaled 
antibiotics in patients with VAT or VAP, and 
describe possible advantages and disadvantages 
of combining inhaled and systemic antibiotics 
for the treatment of these serious infections.
METHODS
An extensive search of the published literature 
including the terms ‘inhaled antibiotics,’ 
‘ inhaled antimicrobials , ’  ‘venti lator-
associated pneumonia,’ ‘ventilator-associated 
tracheobronchitis,’ ‘cystic fibrosis,’ ‘aerosols and 
mechanical ventilation,’ ‘bronchial circulation,’ 
‘biofilms,’ ‘quorum sensing,’ ‘colistin,’ 
‘tobramycin,’ ‘levofloxacin,’ ‘vibrating mesh 
nebulizers,’ and ‘PDDS device’ was conducted. 
In addition, the bibliography of various retrieved 
articles was searched for any relevant papers.
TERMINOLOGY
Clinical features of infection, radiologic 
features, and microbiologic data are employed 
to distinguish airway colonization with bacteria 
from VAT or VAP (Tables 1 and 2). 
Airway Colonization 
Colonization of the lower airways is defined as 
the presence of a microorganism in the lower 
airways without clinical and radiological features 
of infection. A quantitative microbiological 
sample yields less than 105cfu/mL of 
microorganisms.9,10
Ventilator-Associated Tracheobronchitis
The Centers for Disease Control (CDC) defines VAT 
as a tracheobronchial infection that occurs at least 










New or progressive 
infiltrate on chest 
x-ray†
Airway colonization – – ± –
VAT + – + –
VAP‡ + + + +
*At least 2 of the 3 clinical criteria must be present for a diagnosis of VAP.
†The presence of a new infiltrate is the major clinical and radiological distinguishing feature between VAT and VAP. 
However, infiltrates can be difficult to assess in mechanically-ventilated patients.
‡Other clinical characteristics in patients with VAP may include altered mental status, increasing oxygen requirements, and 
auscultatory findings such as crackles or bronchial breath sounds.
VAP=ventilator-associated pneumonia; VAT=ventilator-associated tracheobronchitis. 
Table 1. Definitions of airway colonization, ventilator-associated tracheobronchitis, and ventilator-associated pneumonia - 
clinical and radiologic criteria.
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criteria: (1) patient has no clinical or radiological 
evidence of pneumonia; (2) two of the following 
signs and symptoms in the absence of other 
obvious source: fever (temperature >38°C), cough, 
new or increased sputum production, rhonchi, and 
wheezing; and (3) at least one of the following: a 
positive culture obtained by deep tracheal aspirate 
or bronchoscopy, and positive antigen test on 
respiratory secretions.11 Other investigators 
have based the diagnosis of VAT on similar 
criteria, but the cut-offs employed for positive 
(≥105 or 106 cfu/ml) endotracheal aspirate cultures 
have differed.7-11 Thus, the major difference 
between VAT and VAP is the presence of a new 
or progressive infiltrate on chest x-ray in the 
latter (Table 1). However, chest x-ray findings 
in mechanically ventilated patients can be non-
specific, and many patients already have infiltrates 
at the time of admission to the Intensive Care Unit 
(ICU). Moreover, the quality of films obtained in 
the ICU could limit their sensitivity and specificity 
for detection of new or progressive infiltrates on 
chest x-ray. Because of these limitations, there is 
considerable diagnostic overlap between patients 
with VAT or VAP. 
VAT is thought to be the third most frequent 
ICU-acquired infection, after pneumonia and 
urinary tract infections. Depending on the 
definition employed and the ICU population 
studied, the incidence of VAT in various 
investigations varies from 1.4% to 10.6%.7,8,12,13 A 
systematic review of the literature estimated that 
VAT affected 11.5% of ICU patients receiving 
mechanical ventilation for >48 hours.14
Gram-negative bacteria are the most frequent 
causes of VAT, accounting for 75% of the 
isolates. Pseudomonas aeruginosa, Staphylococcus 
aureus, and Acinetobacter baumannii are the most 
frequent organisms isolated.10 The infection 
is polymicrobial in 22% of cases. Organisms 
causing VAT are often MDR, and VAT is 
associated with prolongation of the duration of 
mechanical ventilation, increased ICU length of 
stay (LOS), and higher ICU mortality, compared 
to patients who do not develop VAT.7,8
Ventilator-Associated Pneumonia
Pneumonia which develops more than 48 hours 









PMNL + Low <105 cfu/ml <104 cfu/ml <103 cfu/ml
VAT PMNL + 
bacteria +†
Moderate to high >105 cfu/ml <104 cfu/ml <103 cfu/ml
VAP‡ PMNL + >5% 
intracellular 
bacteria
Moderate to high >106 cfu/ml >104 cfu/ml >103 cfu/ml
*Specimens obtained before antibiotic administration.
†Presence of bacteria on Gram-stain of ETA roughly correlates with >1x105 cfu/ml of microorganisms.6
‡Diagnosis of VAP is considered to be microbiologically confirmed if significant growth is seen on PSB, BAL, or ETA cultures.
BAL=broncho-alveolar lavage; ETA=endotracheal aspirate; PMNL=polymorphonuclear leukocytes; PSB=protected 
specimen brush; VAP=ventilator-associated pneumonia; VAT=ventilator-associated tracheobronchitis.
Table 2. Definitions of airway colonization, ventilator-associated tracheobronchitis, and ventilator-associated pneumonia - 
microbiologic criteria.*
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Radiologic features include the development 
of new or progressive infiltrate on chest x-ray 
(Table 1). The diagnosis can be confirmed by 
positive blood or pleural fluid cultures similar 
to the tracheal secretions or histopathologic 
evidence of pneumonia, although these 
are positive in a minority of patients.11
A microbiologic confirmation also includes 
quantitative cultures with a bacterial count 
exceeding a diagnostic threshold of 1 x 103 cfu/ml
in a protected brush specimen, >1 x 104 cfu/ml in 
a broncho-alveolar lavage (BAL) fluid specimen, 
or >1 x 106 cfu/ml in an endotracheal aspirate 
specimen (Table 21,11). 
VAP is undoubtedly one of the most 
important infections encountered in 
mechanically-ventilated patients. Enteric 
Gram-negative organisms are a more common 
cause of VAP than Gram-positive organisms, 
although the frequency of MDR Gram-negative 
bacteria and methicillin-resistant Staphylococcus 
aureus (MRSA) infection in ICUs is increasing.15-18 
Early-Onset VAP
VAP occurring in the first 4 days of hospitalization 
is classified as early onset VAP, and is usually 
caused by antibiotic-sensitive bacteria. Potential 
pathogens in early onset-VAP in patients 
with no risk factors for MDR bacteria include 
Streptococcus pneumoniae, Haemophilus influenzae, 
Methicillin-sensitive Staphylococcus aureus, and 
Gram-negative bacteria such as Escherichia coli, 
Klebsiella pneumoniae, Enterobacter species, Proteus 
species, and Serratia marcescens.15-18
Late-Onset VAP
Pneumonia developing ≥5 days after 
hospitalization is usually due to MDR 
pathogens, and is associated with increased 
mortality and morbidity.15-18 Early-onset VAP 
patients who previously received antibiotics or 
were hospitalized within 90 days of their current 
admission are treated as late-onset VAP.1,19 
Other risk factors for MDR pathogens include 
residence in a nursing home, chronic dialysis, 
home infusion therapy, and contact with family 
members harboring MDR pathogens.1,20 Potential 
pathogens in late-onset VAP or in patients 
with risk factors for MDR pathogens include 
Pseudomonas aeruginosa, Acinetobacter species, 
Klebsiella pneumoniae (ESBL strain), MRSA, and 
Legionella pneumophila.16,17 The infection is 
polymicrobial in up to 40% of patients with 
VAP.15-18
THE INTER-RELATIONSHIP 
BETWEEN VAT AND VAP
VAT and VAP share common pathogenetic 
mechanisms; however, opinions differ about 
their inter-relationship. According to one 
view, development of VAT is an intermediate 
step in the continuum from oropharyngeal 
colonization with bacteria to eventual 
occurrence of VAP.6 In the other view, VAT 
is considered a separate clinical entity from 
VAP.7,8 The former view is supported by the 
results of surveillance cultures utilizing serial 
endotracheal aspirate specimens to evaluate 
the relationship between colonization and 
infection.21-24 The pathogen in most instances 
of VAP was present in previous endotracheal 
aspirates before the development of infection,21
and weekly surveillance endotracheal aspirate 
cultures may be helpful in detecting VAP due to 
MDR pathogens.22 Increasing numbers of lower 
respiratory tract pathogens have been shown 
to predict increased virulence and increased 
inflammation.6 In addition, post-mortem studies 
have shown a progression from bronchitis to 
pneumonia in mechanically ventilated ICU 
patients.25 Proponents of this view of progression 
from VAT to VAP recommend frequent 
microbiological monitoring of endotracheal 
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aspirates and treatment for VAT when clinical 
and quantitative culture requirements are met.6 
Recently, a one-year long prospective cohort 
study evaluated the characteristics of VAT in 
patients admitted to a University Hospital.8 
ICU patients were clinically monitored on a 
daily basis for development of VAT or VAP, and 
respiratory cultures obtained when infection 
was suspected. Interestingly, the median onset 
of VAT was 7.5 days after intubation compared 
with 5 days for VAP, ie, onset of VAT occurred 
later than onset of VAP. Among 28 patients with 
VAT, nine patients progressed to VAP despite 
appropriate antibiotic therapy. ICU and hospital 
LOS, duration of mechanical ventilation, 
and hospital mortality were similar between 
patients with VAT and VAP.8 Previously, Nseir 
and colleagues also reported that the median 
time for development of VAT after initiation of 
mechanical ventilation was 10 days in surgical 
patients and 11 days in medical patients.7 
The delayed onset of VAT compared with VAP 
suggests that VAT is an independent entity 
that is associated with significant morbidity, a 
view endorsed by the recent American Thoracic 
Society (ATS)/Infectious Diseases Society of 
America (IDSA) guidelines.1
RATIONALE FOR INHALED 
ANTIBIOTIC THERAPY
Successful treatment of respiratory tract 
infections requires adequate antimicrobial 
concentrations for sufficient duration at 
the site of infection. To be effective in the 
lung, antibiotics must penetrate in adequate 
concentrations into bronchial tissues, 
pulmonary parenchyma, the extracellular lining 
fluid (ELF), intraluminal secretions in the airways 
(sputum), and intraluminal inflammatory 
cells.26 The presence of microorganisms within 
the airway lumen propagates an inflammatory 
response within the airways that could damage 
the airway wall and worsen airway obstruction.27 
Intraluminal bacteria within airways could also 
be a source for subsequent development of 
pneumonia and bacteremia. 
Antibiotic inhalation achieves very high 
local drug concentrations within the lung 
compared to systemic administration of the 
same agent. Palmer and colleagues studied the 
concentrations of aerosolized antibiotics in 
sputum.28,29 The aerosolized antimicrobial agents 
achieved 200-fold greater concentration in the 
respiratory secretions than levels achieved in the 
blood. Compared to systemic therapy with the 
same drugs, inhalation therapy achieved much 
higher sputum concentrations with potentially 
lower systemic toxicity.28,29 Moreover, in patients 
with VAT, aerosolized antibiotics reduced the 
volume of purulent tracheal secretions without 
increasing the rate of microbial resistance.28
Antibiotic Penetration via Bronchial Versus 
Pulmonary Circulation
After systemic administration, antibiotic 
concentrations achieved in the ELF depend 
on the penetration across the pulmonary 
vasculature, which has a nonfenestrated 
endothelium.30 Some lipophilic agents, 
such as aminoglycosides, beta-lactams, and 
carbapenems, penetrate effectively into the 
ELF regardless of the presence of inflammation, 
and they achieve adequate antibiotic 
concentrations in respiratory secretions.31 
In contrast, nonlipophilic agents, including 
quinolones, newer macrolides, tetracyclines, 
and clindamycin, depend on the presence 
of inflammation for adequate penetration.31 
Moreover, many tight junctions in the alveolar 
epithelium make it relatively impermeable 
to drugs. In contrast, drug penetration from 
the bronchial circulation is facilitated by the 
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presence of a fenestrated endothelium,32 and 
penetration is further enhanced by the presence 
of inflammation.26 After systemic administration, 
transport of antibiotics across the bronchial 
epithelium is also limited by tight junctions so 
that intraluminal antibiotic concentrations tend 
to be much lower than serum levels.33 Thus, 
there is limited antibiotic penetration into the 
ELF, airway lumen, and intraluminal secretions 
after systemic antibiotic administration.34-36
Furthermore, inhibitory factors in sputum34,35 
could prevent eradication of organisms unless 
high antibiotic concentrations are achieved 
within sputum. 
Inhaled antibiotics, on the other hand, 
achieve high concentrations in sputum, are 
mainly absorbed via the bronchial epithelium, 
and are rapidly distributed by a rich network 
of sub-mucosal capillaries to other areas of 
the lung, including the lung parenchyma.37
After inhalation, uptake through the bronchial 
mucosa should lead to significantly higher 
antibiotic concentrations at various sites 
in the lung, including the bronchial and 
pulmonary tissues. Thus, a two-pronged attack 
by combining systemically administered and 
inhaled antibiotics may be more effective in 
achieving uniformly high antibiotic levels in 
various lung compartments than those achieved 
by systemic antibiotics alone. 
Optimizing Antibiotic Levels in the Lung
Inhaled antibiotics undoubtedly achieve high 
local concentrations within the lung, however 
to be effective the drugs need to diffuse through 
sputum and enhance bacterial killing. In 
patients with cystic fibrosis (CF), aerosolization 
of gentamicin achieved higher levels and 
more central aerosol deposition in the lung in 
patients with lower forced expiratory volume 
in one second (FEV1).38 The concentrations 
of drug achieved in bronchial secretions of 
patients with CF directly correlate with clinical 
efficacy of antimicrobial treatment,39 and 
high concentrations of tobramycin have been 
reported in lung tissues after nebulization, while 
maintaining serum levels at very low levels.40
Several investigators employed methods to 
optimize drug delivery to the lower respiratory 
tract of mechanically-ventilated patients.41,42 
O’Doherty and colleagues described wide 
variability in the efficiency of nebulized drug 
delivery to mechanically-ventilated patients 
depending on the dose, volume of fill, and the 
type of nebulizer employed.43 The efficiency of 
drug delivery could be enhanced several-fold by 
employing specialty jet nebulizers that produce 
an aerosol with a high fine-particle fraction, and 
by optimizing ventilator settings and turning 
off humidification in the ventilator circuit.29,44-46
With optimal methods of drug delivery, Palmer 
and colleagues47 consistently achieved antibiotic 
concentrations in tracheal aspirates that 
were 20- to 100-fold higher than the in-vitro 
Minimum Inhibitory Concentrations (MICs) of 
the organisms being treated.  Newer generation 
nebulizers have further improved the efficiency 
of drug delivery.48 A newer generation nebulizer 
(Aeroneb Pro®, Aerogen, Galway, Ireland) with 
a high efficiency of drug delivery49 was able 
to achieve high amikacin concentrations in 
lung tissues.50 The next generation Pulmonary 
Drug Delivery System (PDDS)51 has an even 
higher efficiency of delivering antibiotics; in 
mechanically-ventilated patients with VAP, it 
provided amikacin concentrations in ELF that 
were higher than the MIC for Gram-negative 
microorganisms while maintaining serum 
concentrations below nephrotoxic levels.52
In contrast to Gram-negative infections, 
only a few investigators have examined the 
effect of inhaled vancomycin for Gram-positive 
infections.28,53 Similarly to aminoglycosides, 
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sputum concentrations of aerosolized 
vancomycin in mechanically-ventilated 
patients were 20-fold higher compared to those 
achieved after intravenous administration,53
and use of aerosolized vancomycin enhanced 
clinical and microbiological outcomes of 
treatment.28
In patients with CF, inhaled levofloxacin 
achieves high concentrations within sputum,54 
retains its bactericidal effects in the presence 
of sputum, and achieves rapid bacterial killing 
within 30 minutes.55 Moreover, levofloxacin had 
greater bactericidal activity against Pseudomonas 
aeruginosa isolates from CF patients as compared 
to tobramycin or amikacin.56 However, to 
the best of our knowledge, there is as yet no 
published clinical experience with inhaled 
levofloxacin in patients with VAT or VAP. 
Biofilm Formation and Quorum Sensing
Formation of a biofilm on the inner surface 
of the endotracheal tube is thought to be 
an important factor in the development of 
VAP.57,58 The presence of a biofilm reduces 
the intraluminal diameter of endotracheal 
tubes,59 hinders the ability to cough up 
bacteria and secretions from the lower airways, 
and increases the need for tracheobronchial 
suctioning. Planktonic forms displaced from 
the biofilm by suction catheters or by the 
shearing action of inspiratory airflow during 
positive pressure ventilation have the potential 
to cause pneumonia.57,60 Several common 
organisms causing VAP, such as Pseudomonas 
aeruginosa, MRSA, Acinetobacter baumannii, 
Klebsiella pneumoniae, and Enterobacter cloacae
are capable of forming biofilms. Within the 
biofilm, these bacteria grow slowly in layers 
embedded within a glycocalyx57,60-62 that 
reduces the rate of antibiotic diffusion into 
bacterial cells,63 makes them resistant to 
antibiotic killing, and promotes emergence of 
resistant phenotypes. 
At a high bacterial density, the phenomenon 
of “quorum sensing” (QS) facilitates production 
of virulence factors and further promotes 
biofilm formation.58,64 QS provides a mechanism 
for bacteria to sense their environment and 
coordinate expression of various genes within 
the entire bacterial population.65 QS also 
controls synthesis and secretion of a number of 
virulence factors.66,67
Pseudomonas aeruginosa possesses two distinct 
but interacting QS systems, Las and rhl, with 
the former controlling the latter system.68 
Most strains of Pseudomonas aeruginosa initially 
colonizing intubated patients are QS-proficient.69
In critically ill patients, Le Berre and coworkers66 
showed that most Pseudomonas aeruginosa strains 
associated with VAP had increased expression of 
elastase and pyocyanin. However, these studies 
were conducted in in vitro conditions, which 
may differ considerably from conditions in 
vivo, where the microenvironment in which 
Pseudomonas aeruginosa grows may modify the 
phenotypic characteristics of the strains.
Favre-Bonte and colleagues64 found that auto-
inducers (AI) are produced during colonization of 
intubated patients with Pseudomonas aeruginosa. 
However, the precise AI produced differed 
between isolates obtained from intubation 
devices versus those obtained concurrently from 
tracheal aspirates. QS inhibition could affect 
isolates growing inside the biofilm in intubation 
devices differently from those residing in 
the lungs. They concluded that isolates from 
tracheal aspirates produced significantly more 
elastase but less biofilm, and had marginally 
reduced adhesion capacity than isolates from 
the intubation devices.64
The importance of QS for pathogenesis of 
VAP is supported by the observations of Kohler 
and colleagues.70 This study found that most 
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mechanically-ventilated patients were initially 
colonized with QS-deficient Pseudomonas 
aeruginosa isolates, but those who were initially 
colonized with QS-proficient isolates had 
a higher incidence of VAP, especially those 
colonized with strains of Pseudomonas aeruginosa 
that produced high levels of rhamnolipids, a 
QS-dependent virulence factor. Moreover, only 
those patients who developed VAP showed 
evidence of in vivo QS gene induction.70 
Antagonists that could inhibit intercellular 
communication in Pseudomonas aeruginosa 
biofilms have been suggested as new preventive/
therapeutic strategies for Pseudomonas aeruginosa 
infections.71
Antibiotic treatment for increased numbers 
of bacteria in endotracheal aspirates, even in the 
absence of clinical signs of infection, could have 
beneficial effects by reducing the production of 
virulence factors. In mechanically-ventilated 
patients with newly acquired Pseudomonas 
aeruginosa infection, a high microorganism 
burden was associated with secretion of the type 
III secretion facilitator protein (PcrV), and the 
risk of death was significantly higher in these 
patients despite antibiotic treatment.72 Likewise, 
Matsushima and colleagues administered 
antibiotics according to ATS/IDSA guidelines 
to 133 patients based on positive Gram stains 
of endotracheal aspirates and compared the 
outcomes to a prior control group of 128 
patients who had not received antibiotic 
therapy.73 Such pre-emptive antibiotic therapy, 
regardless of clinical and radiological evidence 
of VAP, reduced the incidence of subsequent 
VAP without increasing overall antibiotic use; 
the frequency of developing Acute Respiratory 
Distress Syndrome (ARDS) and VAP-associated 
mortality rate were also decreased.73 Although 
this study was not randomized, these 
provocative observations highlight the need for 
prospective randomized controlled trials (RCT) 
to further explore the role of earlier intervention 
with antibiotics in critically ill patients with a 
high bacterial burden.
After systemic administration, the low 
antibiotic concentrations achieved within the 
airway lumen have the potential to induce 
biofilm formation.74 In contrast, inhaled 
antibiotics achieve high local concentrations 
that could suppress biofilm formation, inhibit 
bacterial growth within the biofilm,75 decrease 
the potential for QS, and reduce the emergence 
of MDR bacteria. Thus, the role of inhaled 
antibiotics in potentially reducing or disrupting 
biofilm formation and decreasing the emergence 
of MDR organisms requires further investigation.
In the context of biofilm formation and 
development of VAP, it is interesting to note 
that the use of silver-coated endotracheal tubes, 
which inhibit biofilm formation, reduced the 
incidence of VAP, and delayed time to VAP 
occurrence.76 Recently, gardine (a combination 
of two antiseptics, namely brilliant green and 
chlorhexidine) or gendine (a combination 
of gentian violet and chlorhexidine)-coated 
endotracheal tubes were found to be superior to 
silver coated endotracheal tubes in preventing 
biofilm formation by MRSA, Pseudomonas 
aeruginosa, Acinetobacter baumannii, Klebsiella 
pneumoniae, Enterobacter cloacae, and Candida 
albicans.77 Future RCT are needed to evaluate 
the effects of gardine and gendine-coated 
endotracheal tubes on prevention of VAP and 
ICU mortality. 
DRUGS EMPLOYED FOR INHALED 
ANTIBIOTIC THERAPY
In the past, intravenous formulations of 
antibiotics that contained preservatives, 
such as phenol and bisulfites, were used for 
inhalation. Ideally, solutions employed for 
inhalation must be sterile, nonpyrogenic, and 
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preservative free. They should also be pH, 
osmolality, and salinity adjusted to minimize 
airway irritation.4 Several antibiotics, 
including tobramycin, colistin, polymyxin 
B, gentamicin, amikacin, ceftazidime, 
vancomycin, aztreonam, amphotericin 
B, pentamidine, ribavirin, and zanamavir 
have been administered by inhalation.78 In 
mechanically-ventilated patients, inhaled 
tobramycin and colistin are often employed 
as these two antibiotics have been specifically 
formulated in solutions for aerosolized 
delivery.4,78 Amikacin by inhalation (NKTR-
061) is in clinical trials for treatment of 
Gram-negative VAP.52 The US Food and Drug 
Administration (FDA) has recently approved 
an inhaled liposomal nanoparticle formulation 
of amikacin (Arikace®, Transave Inhalation 
Biotherapeutics, Monmouth Junction, NJ) and 
inhaled aztreonam (Cayston®, Gilead Sciences, 
Foster City, CA) for treatment of Pseudomonas 
aeruginosa infection in patients with CF. 
Likewise, the use of inhaled levofloxacin has 
shown promising results in CF patients.79
TREATMENT OF VAT WITH 
INHALED ANTIMICROBIALS
Inhaled antibiotic therapy may prevent 
progression from VAT to VAP in some patients. 
In a randomized, blinded, placebo-controlled 
trial, 43 patients were randomized to receive 
aerosolized antibiotics versus placebo (saline) 
for 14 days.28 Compared to the placebo group, 
the use of inhaled and systemic antibiotics 
was associated with lower rates of VAP, faster 
weaning from the ventilator, reduced number 
of MDR pathogens, and lesser use of systemic 
antibiotics.28 The lack of quantitative cultures 
of endotracheal aspirates, and the presence of 
prior VAP in a high number of patients, were 
significant limitations of this study. 
A consensus regarding treatment of VAT with 
antibiotics has remained elusive. Some experts 
recommend treatment, especially for those 
patients with VAT who have underlying disease 
or exhibit weaning difficulties,10,28,80 whereas 
others argue in favor of treating VAT only 
when there is infection with MDR organisms 
in an attempt to reduce morbidity and prevent 
progression to VAP.81-83
Prospective observational case-control 
studies in mechanically-ventilated patients 
with chronic obstructive pulmonary disease 
(COPD),84 and those without chronic respiratory 
disease,85 found that patients with VAT had 
longer durations of mechanical ventilation 
and ICU stay, but occurrence of VAT did not 
impact mortality rates. A later, prospective, 
randomized, controlled multicenter study 
in patients with VAT86 found that the group 
who received antibiotics had more ventilator-
free days (median 12 days versus 2), lower 
subsequent development of VAP (13% 
versus 47%), and lower ICU mortality rates 
(18% versus 47%), but no differences were 
observed in duration of mechanical ventilation 
or ICU LOS compared to patients who did not 
receive antibiotics.86 However, this study was 
not blinded and antibiotic therapy was not 
standardized. Moreover, because the trial had 
to be stopped early there were a smaller total 
number of patients than planned and there 
was an imbalance in the number of patients 
assigned to the antibiotic and control groups.86 
Nevertheless, these findings stress the need for 
further studies to investigate the efficacy of 
appropriate antibiotics in patients with VAT. 
A meta-analysis of published studies14 found 
that use of antimicrobial agents (systemic 
with or without inhaled antibiotics) for VAT 
reduced the frequency of subsequent episodes 
of pneumonia and increased ventilator-free 
days. However, antibiotic usage for VAT did not 
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lower mortality, shorten ICU LOS, or reduce 
duration of mechanical ventilation compared 
to patients receiving placebo or no treatment.14 
The lack of convincing evidence to support the 
use of inhaled antibiotics has led some experts 
to caution against their use for the treatment of 
VAT on the grounds that inhaled antibiotics are 
ineffective and their routine use could promote 
the emergence of resistant bacteria.87 Clearly, 
more data are needed to establish the appropriate 
role of inhaled antibiotics for treatment of VAT.
TREATMENT OF VAP WITH 
INHALED ANTIBIOTICS
Treatment of VAP depends on the onset of VAP 
and the risk factors for MDR pathogens. The 
choice of antibiotics should be modified based 
on knowledge of the predominant pathogens 
and the local antibiotic susceptibilities which are 
variable among different clinical institutions.88 
Inappropriate selection of initial antibiotics 
is associated with increasing antimicrobial 
resistance89 and excess hospital mortality.90,91
Treatment of VAP with Systemic and Inhaled 
Antibiotics
Recommended antibiotics in early-onset VAP 
with no risk factors for MDR pathogens include 
ceftriaxone, fluoroquinolones, ampicillin/
sulbactam, or ertapenem. Combination 
antibiotic therapy is indicated for late-onset VAP 
and patients at high risk for MDR pathogens. 
This includes antipseudomonal cephalosporins 
(cefepime, ceftazidime), antipseudomonal 
carbapenem (imipenem, meropenem, or 
doripenem), or beta-lactam/beta-lactamase 
inhibitor combination (piperacillin/tazobactam 
or ticarcillin/clavulanate), or a monobactam 
(aztreonam) plus an antipseudomonal 
fluoroquinolone (ciprofloxacin or levofloxacin), 
or aminoglycosides (amikacin, gentamicin, 
or tobramycin) plus linezolid, or vancomycin 
if there is suspicion of MRSA infection.1 Once 
the results of respiratory tract cultures are 
available, it is usually possible to de-escalate 
the therapy,92,93 and such an approach reduces 
mortality in patients with VAP compared to 
those in whom therapy is not de-escalated.92-95
Despite timely initiation of appropriate 
antibiotic therapy and other supportive 
measures, VAP continues to be associated with 
significant mortality.1,15,92 Therefore, alternative 
methods of treatment, including the addition 
of inhaled antimicrobials, are being explored 
to try and reduce VAP-associated morbidity and 
mortality.  
The use of inhaled antimicrobials in patients 
with VAP has been extensively reviewed in 
recent years.4,5,96-98 The consensus of opinion 
is that inhaled antimicrobials should only be 
employed as an adjunct to systemic antibiotic 
therapy; only a few RCT have evaluated the 
use of inhaled antibiotics, and their role in 
treatment of VAP remains inconclusive.4,5,96-98 
Some recent studies lend support to the use of 
inhaled antimicrobials for VAP. Czosnowski and 
coworkers administered inhaled and parenteral 
antibiotics for the treatment of VAP.99 In patients 
with bacteriologically confirmed VAP, there were 
45 episodes of Pseudomonas aeruginosa infection; 
14 with Acinetobacter baumannii; and one with 
both organisms. Clinical success was achieved in 
>70% of infections, including those due to MDR 
organisms.99 Likewise, inhaled aminoglycosides 
administered to cancer patients with Gram-
negative VAP provided greater clinical and 
microbiological success compared to a group 
receiving intravenous antibiotics alone.100 
A double blind, placebo-controlled study in 
ventilator-dependent patients with Gram-
negative VAP found that when patients were 
given adjunctive inhaled amikacin 400 mg twice 
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daily with the PDDS delivery system in addition 
to systemic antibiotics, the requirement for 
systemic antibiotics on day 7 was reduced to 
one-half of that in patients receiving placebo 
inhalations.101 Thus, addition of inhaled 
antibiotics may reduce the requirement for 
systemic antibiotics, and could help in reducing 
the duration of therapy.
A meta-analysis that included five RCT102 
reported that administration of antimicrobials 
via the respiratory tract (either inhaled or 
endotracheally instilled) was associated with 
better treatment success as compared to 
controls, but there was no significant effect on 
all-cause mortality. Among the five RCT, there 
were only two reports where the antibiotic was 
administered by aerosol, whereas antibiotics 
were endotracheally instilled in the remaining 
three studies. Among the aerosolized antibiotic 
group, the total number of patients that were 
clinically evaluable was very small. This meta-
analysis102 highlights the paucity of high-quality 
data in the published literature, and emphasizes 
the need for further studies to establish the role 
of inhaled antibiotics in patients with VAP.  
The long-held view that inhaled antibiotics 
should not be employed as monotherapy for 
VAP was recently challenged by an elegant, 
randomized, phase 2 trial in patients with 
VAP caused by Pseudomonas aeruginosa.103 
Patients receiving only nebulized ceftazidime 
and amikacin had clinical and bacteriological 
responses that were similar to those receiving 
intravenous ceftazidime and amikacin (or 
ciprofloxacin for three patients infected with 
organisms that showed intermediate resistance). 
The nebulized treatment was well tolerated and 
there was no increase in emergence of resistant 
organisms or the incidence of superinfection 
by other organisms.103 This was, however, 
a single-center study that included only 
40 patients, and patients with severe pneumonia 
or extrapulmonary infection were excluded. 
Nevertheless, the challenging findings of 
Lu and colleagues103 strongly suggest the need 
for further investigating the role of monotherapy 
with inhaled antibiotics in a larger cohort of 
patients with moderately severe VAP. 
Treatment of VAP due to MDR Organisms
When aerosolized antibiotics are employed 
in targeted, time limited protocols, they can 
be very effective in the management of MDR 
microorganisms in patients with VAP.46 In 
22 surgical ICU patients with VAP, aerosolized 
aminoglycosides (16 patients with tobramycin 
and six patients with amikacin) were 
administered with parenteral antibiotics for VAP. 
The average duration of mechanical ventilation 
in these patients was 4.3 days; there were no 
renal or pulmonary complications and 19 of the 
22 patients survived.104
The emergence of MDR strains of Pseudomonas 
aeruginosa and Acinetobacter baumannii that are 
associated with a very high mortality rate105 
led to the recent revival of interest in the use 
of colistin.106 Parenteral or inhaled colistin has 
been employed as the last line of defense against 
these organisms. Several retrospective case series 
have reported on the use of parenteral colistin in 
the treatment of pneumonia and other serious 
infections in patients who did not have CF.107-113
These investigators have shown a consistent 
clinical efficacy (>50% efficacy in most studies), 
an acceptable toxicity profile, and the lack of 
emergence of colistin-resistant P. aeruginosa 
and A. baumannii strains. Within the past 
5 years, there have been at least three prospective 
case series where intravenous colistin has been 
employed for infections with Acinetobacter 
baumannii and Pseudomonas aeruginosa in 
ICU patients.114-116 The majority of infections 
were due to pneumonia caused by organisms 
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that were sensitive only to colistin. A favorable 
clinical and microbiological response was 
reported in all three studies with acceptable 
levels of nephrotoxicity.114-116
The experience with inhaled colistin 
as an adjunct to parenteral antibiotics for 
treatment of VAP caused by MDR Gram-
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Table 3. Treatment with inhaled colistin for infections due to multi-drug resistant Gram-negative infections.
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than that with parenteral colistin (Table 3). 
Most studies have been retrospective analyses 
of small number of patients81,83,117-122 with 
pneumonia due to MDR Acinetobacter baumannii
or Pseudomonas aeruginosa. Despite the serious 
nature of these infections, administration 
of inhaled colistin in addition to systemic 
antibiotic therapy (including parenteral colistin) 
provided encouraging results, with clinical 
and microbiological success in the majority of 
treated patients (Table 3). Significantly, colistin-
resistant isolates were not reported in these 
studies, even among patients with persistently 
positive cultures for Pseudomonas aeruginosa 
or Acinetobacter baumannii. Falagas and 
coworkers122 reported an 80% success rate with 
inhaled colistin alone, without concomitant 
intravenous colistin, in patients with VAP (n=3) 
and nosocomial pneumonia (n=2) caused by 
MDR Gram-negative organisms. Thus, inhaled 
colistin could be employed in critically ill 
patients with MDR Gram-negative pneumonia 
provided that recommended dosages are used, 
renal function is closely monitored, and other 
potentially nephrotoxic agents are avoided. 
In patients with nosocomial pneumonia 
(most caused by MDR Pseudomonas aeruginosa), 
who were failing intravenous therapy, 
improvement or cure in the vast majority (93%) 
of patients was noted with the use of inhaled 
polymyxin B.83 Moreover, all five patients with 
tracheobronchitis showed improvement or were 
cured following inhaled polymyxin B alone, 
without systemic antibiotics.83 The authors 
concluded that inhaled polymyxin B could be 
considered as a salvage therapy for patients with 
nosocomial pneumonia or tracheobronchitis 
caused by MDR Gram-negative bacilli who are 
failing intravenous antibiotic treatment.83
Thus, there is an increasing interest in use of 
aerosolized antibiotics for treating patients with 
VAP. Further research is needed to determine the 
optimum methods of drug delivery, appropriate 
dosages, and frequency of drug administration.123
Duration of Treatment
The duration of inhaled antibiotic therapy in 
the published studies varied from 7 to 14 days 
or longer. However, there is no conclusive 
information on the optimal duration of therapy. 
In view of recent data showing that therapy 
of VAP with systemic antibiotics could be 
shortened124,125 without compromising patient 
outcomes, it may be possible to limit inhaled 
antibiotic therapy to a course of 7 to 8 days. 
Lu and colleagues achieved treatment success in 
70% of patients receiving nebulized amikacin 
and ceftazidime (15 mg.kg-1.3h-1) for 3 days and 
mean 4.9 ± (1SD) 1.2 days, respectively.103
DISADVANTAGES OF INHALED 
ANTIBIOTICS
Adverse effects due to inhaled antibiotics may be 
due to local irritant effects on the airways or due 
to toxicity of the systemically absorbed drug.4 
The local effects are mainly related to cough 
and bronchospasm, which can be reduced by 
use of appropriate preservative-free formulations 
designed for inhalation, and pre-treatment 
with beta-agonist bronchodilators.4 Systemic 
absorption of aminoglycosides can produce renal 
toxicity, and appropriate dosing adjustments 
are needed in patients with renal failure 
who receive inhaled aminoglycosides.126,127
In mechanically-ventilated patients with Gram-
negative pneumonia and acute renal failure who 
were receiving inhaled amikacin twice daily, 
continuous veno-venous hemodiafiltration 
was effective at maintaining serum trough 
concentrations within acceptable limits and 
serious adverse events were not reported.126 
Single doses of inhaled amikacin are well 
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tolerated in patients with chronic kidney 
disease and dialysis is effective in clearing the 
drug from the circulation in patients with 
end stage renal disease.127 Similarly, colistin 
inhalation carries the risk of nephrotoxicity 
and neurotoxicity.128 Colistin should be mixed 
with diluent immediately before use because 
it can be hydrolyzed to a toxic metabolite 
which can cause direct lung injury and lead to 
acute respiratory distress syndrome (ARDS).129 
In clinical studies, toxic effects to inhaled 
antibiotics are infrequent, and the drugs needed 
to be discontinued because of adverse effects 
in a very small proportion of patients. The 
indiscriminate use of inhaled antibiotics could 
lead to emergence of drug resistant organisms.130
Thus, inhaled antibiotics should only be 
employed in targeted, time-limited protocols. 
CONCLUSION
The potential role of inhaled antibiotics for the 
treatment of VAP is recognized by international 
guidelines. Aerosolized antibiotics used as an 
adjunct to systemic antibiotic therapy have 
shown beneficial effects for management 
of VAP,99,102 including VAP caused by MDR 
pathogens where systemic therapy alone is 
ineffective. The routine use of aerosolized 
antibiotics cannot be recommended for VAP 
treatment; however, in situations where 
systemic therapy alone is failing, when systemic 
therapy is denied by patients, intravenous access 
is not available or concerns of systemic toxicity 
exist, the option of nebulized antibiotics should 
be considered. When used in management of 
VAT, inhaled antibiotics reduce the frequency 
of VAP and facilitate weaning, but a reduction 
in mortality has not been observed.8,10,28 With 
the availability of newer generation nebulizers, 
that consistently deliver drugs to the lower 
respiratory tract with a high efficiency, and 
antibiotic formulations that are specifically 
designed for inhalation, future prospective, 
randomized, placebo-controlled trials will help 
to further establish the role of inhaled antibiotics 
for treatment of VAT and VAP. 
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